Epidemiology of sepsis: Recent advances

被引：77

作者：

Danai P. ^{[1
]}

Martin G.S. ^{[1
]}

机构：

[1] Emory University School of Medicine, Atlanta, GA 30303

来源：

Current Infectious Disease Reports | 2005年 / 7卷 / 5期

关键词：

Septic Shock; Severe Sepsis; Systemic Inflammatory Response Syndrome; Respir Crit; Sepsis Patient;

D O I：

10.1007/s11908-005-0005-1

中图分类号：

学科分类号：

摘要：

Sepsis, as defined by an expert consensus definition, is the development of the systemic inflammatory response syndrome in the presence of infection. Using this clinically applicable definition, several studies have evaluated the epidemiology of sepsis over the past decade. The current incidence of sepsis is at least 240 patients per 100,000 people in the United States population, whereas for severe sepsis it is between 51 and 95 patients per 100,000 people. The incidence rate for sepsis has been increasing over the past two decades, driving an increase in the number of deaths despite a decline in case-fatality rates. Sepsis is the tenth leading cause of death in the United States and accounts for more than 17 billion dollars in direct healthcare expenditures. Copyright © 2005 by Current Science Inc.

引用

页码：329 / 334

页数：5

共 25 条

[1]

Bone R.C., Balk R.A., Cerra F.B., Et al., Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, Chest, 101, pp. 1644-1655, (1992)

[2]

Bone R.C., Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome), JAMA, 268, pp. 3452-3455, (1992)

[3]

Bernard G.R., Vincent J.L., Laterre P.F., Et al., Efficacy and safety of recombinant human activated protein C for severe sepsis, N. Engl. J. Med., 344, pp. 699-709, (2001)

[4]

Warren B.L., Eid A., Singer P., Et al., High-dose antithrombin III in severe sepsis: A randomized controlled trial, JAMA, 286, pp. 1869-1878, (2001)

[5]

Abraham E., Reinhart K., Opal S., Et al., Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial, JAMA, 290, pp. 238-247, (2003)

[6]

Rangel-Frausto M.S., Pittet D., Costigan M., Et al., The Natural History of the Systemic Inflammatory Response Syndrome (SIRS): A Prospective Study, JAMA, 273, pp. 117-123, (1995)

[7]

Brun-Buisson C., Doyon F., Carlet J., Et al., Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units, JAMA, 274, pp. 968-974, (1995)

[8]

Sands K.E., Bates D.W., Lanken P.N., Et al., Epidemiology of sepsis syndrome in 8 academic medical centers, JAMA, 278, pp. 234-240, (1997)

[9]

Angus D.C., Wax R., Epidemiology of sepsis: An update, Crit. Care Med., 29, (2001)

[10]

Increase in national hospital discharge survey rates for septicemia: United States, 1979-1987, MMWR Morb. Mortal Wkly. Rep., 39, pp. 31-34, (1990)

← 1 2 3 →